Global Viral Vector-Based Cell & Gene Therapy CDMO Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Viral Vector-Based Cell & Gene Therapy CDMO market size was valued at US$ 146 million in 2024 and is forecast to a readjusted size of USD 329 million by 2031 with a CAGR of 12.6% during review period.
Viral vector-based cell and gene therapy CDMO refers to a contract research and development and production organization (CDMO) that focuses on providing professional R&D and production services for viral vector-based cell and gene therapy products to biopharmaceutical companies. These services cover everything from the design and optimization of viral vectors to large-scale production in accordance with GMP (Good Manufacturing Practice) standards, as well as product quality control and safety assurance.
This report is a detailed and comprehensive analysis for global Viral Vector-Based Cell & Gene Therapy CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Viral Vector-Based Cell & Gene Therapy CDMO market size and forecasts, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Cell & Gene Therapy CDMO market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Cell & Gene Therapy CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Cell & Gene Therapy CDMO market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Viral Vector-Based Cell & Gene Therapy CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Viral Vector-Based Cell & Gene Therapy CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, Exothera, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Viral Vector-Based Cell & Gene Therapy CDMO market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Viral Vector-Based Cell & Gene Therapy CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Viral Vector-Based Cell & Gene Therapy CDMO, with revenue, gross margin, and global market share of Viral Vector-Based Cell & Gene Therapy CDMO from 2020 to 2025.
Chapter 3, the Viral Vector-Based Cell & Gene Therapy CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Viral Vector-Based Cell & Gene Therapy CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vector-Based Cell & Gene Therapy CDMO.
Chapter 13, to describe Viral Vector-Based Cell & Gene Therapy CDMO research findings and conclusion.
Viral vector-based cell and gene therapy CDMO refers to a contract research and development and production organization (CDMO) that focuses on providing professional R&D and production services for viral vector-based cell and gene therapy products to biopharmaceutical companies. These services cover everything from the design and optimization of viral vectors to large-scale production in accordance with GMP (Good Manufacturing Practice) standards, as well as product quality control and safety assurance.
This report is a detailed and comprehensive analysis for global Viral Vector-Based Cell & Gene Therapy CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Viral Vector-Based Cell & Gene Therapy CDMO market size and forecasts, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Cell & Gene Therapy CDMO market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Cell & Gene Therapy CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Cell & Gene Therapy CDMO market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Viral Vector-Based Cell & Gene Therapy CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Viral Vector-Based Cell & Gene Therapy CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, Exothera, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Viral Vector-Based Cell & Gene Therapy CDMO market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Adeno-associated Viral
- Adenoviral
- Lentiviral
- Retroviral
- Gene Therapy
- Cell Therapy
- Vaccine Development
- AGC Biologics
- Lonza
- Charles River Laboratories
- Thermo Fisher Scientific
- SK pharmteco
- Exothera
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Viral Vector-Based Cell & Gene Therapy CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Viral Vector-Based Cell & Gene Therapy CDMO, with revenue, gross margin, and global market share of Viral Vector-Based Cell & Gene Therapy CDMO from 2020 to 2025.
Chapter 3, the Viral Vector-Based Cell & Gene Therapy CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Viral Vector-Based Cell & Gene Therapy CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vector-Based Cell & Gene Therapy CDMO.
Chapter 13, to describe Viral Vector-Based Cell & Gene Therapy CDMO research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Viral Vector-Based Cell & Gene Therapy CDMO by Type
1.3.1 Overview: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type in 2024
1.3.3 Adeno-associated Viral
1.3.4 Adenoviral
1.3.5 Lentiviral
1.3.6 Retroviral
1.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Market by Application
1.4.1 Overview: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Gene Therapy
1.4.3 Cell Therapy
1.4.4 Vaccine Development
1.5 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size & Forecast
1.6 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast by Region
1.6.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region, (2020-2031)
1.6.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
1.6.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
1.6.6 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 AGC Biologics
2.1.1 AGC Biologics Details
2.1.2 AGC Biologics Major Business
2.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.1.4 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 AGC Biologics Recent Developments and Future Plans
2.2 Lonza
2.2.1 Lonza Details
2.2.2 Lonza Major Business
2.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.2.4 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Lonza Recent Developments and Future Plans
2.3 Charles River Laboratories
2.3.1 Charles River Laboratories Details
2.3.2 Charles River Laboratories Major Business
2.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.3.4 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Charles River Laboratories Recent Developments and Future Plans
2.4 Thermo Fisher Scientific
2.4.1 Thermo Fisher Scientific Details
2.4.2 Thermo Fisher Scientific Major Business
2.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.4.4 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.5 SK pharmteco
2.5.1 SK pharmteco Details
2.5.2 SK pharmteco Major Business
2.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.5.4 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 SK pharmteco Recent Developments and Future Plans
2.6 Exothera
2.6.1 Exothera Details
2.6.2 Exothera Major Business
2.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.6.4 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Exothera Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Viral Vector-Based Cell & Gene Therapy CDMO by Company Revenue
3.2.2 Top 3 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share in 2024
3.2.3 Top 6 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share in 2024
3.3 Viral Vector-Based Cell & Gene Therapy CDMO Market: Overall Company Footprint Analysis
3.3.1 Viral Vector-Based Cell & Gene Therapy CDMO Market: Region Footprint
3.3.2 Viral Vector-Based Cell & Gene Therapy CDMO Market: Company Product Type Footprint
3.3.3 Viral Vector-Based Cell & Gene Therapy CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value and Market Share by Type (2020-2025)
4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2025)
5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
6.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2031)
6.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
6.3.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2031)
6.3.2 United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
6.3.3 Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
6.3.4 Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
7.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2031)
7.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
7.3.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2031)
7.3.2 Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7.3.3 France Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7.3.5 Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7.3.6 Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region
8.3.1 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2020-2031)
8.3.2 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.3 Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.4 South Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.5 India Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.7 Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
9.2 South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2031)
9.3 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
9.3.1 South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2031)
9.3.2 Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
9.3.3 Argentina Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
10.3.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2031)
10.3.2 Turkey Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
10.3.4 UAE Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Drivers
11.2 Viral Vector-Based Cell & Gene Therapy CDMO Market Restraints
11.3 Viral Vector-Based Cell & Gene Therapy CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Viral Vector-Based Cell & Gene Therapy CDMO Industry Chain
12.2 Viral Vector-Based Cell & Gene Therapy CDMO Upstream Analysis
12.3 Viral Vector-Based Cell & Gene Therapy CDMO Midstream Analysis
12.4 Viral Vector-Based Cell & Gene Therapy CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Viral Vector-Based Cell & Gene Therapy CDMO by Type
1.3.1 Overview: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type in 2024
1.3.3 Adeno-associated Viral
1.3.4 Adenoviral
1.3.5 Lentiviral
1.3.6 Retroviral
1.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Market by Application
1.4.1 Overview: Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Gene Therapy
1.4.3 Cell Therapy
1.4.4 Vaccine Development
1.5 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size & Forecast
1.6 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast by Region
1.6.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region, (2020-2031)
1.6.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
1.6.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
1.6.6 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 AGC Biologics
2.1.1 AGC Biologics Details
2.1.2 AGC Biologics Major Business
2.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.1.4 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 AGC Biologics Recent Developments and Future Plans
2.2 Lonza
2.2.1 Lonza Details
2.2.2 Lonza Major Business
2.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.2.4 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Lonza Recent Developments and Future Plans
2.3 Charles River Laboratories
2.3.1 Charles River Laboratories Details
2.3.2 Charles River Laboratories Major Business
2.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.3.4 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Charles River Laboratories Recent Developments and Future Plans
2.4 Thermo Fisher Scientific
2.4.1 Thermo Fisher Scientific Details
2.4.2 Thermo Fisher Scientific Major Business
2.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.4.4 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.5 SK pharmteco
2.5.1 SK pharmteco Details
2.5.2 SK pharmteco Major Business
2.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.5.4 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 SK pharmteco Recent Developments and Future Plans
2.6 Exothera
2.6.1 Exothera Details
2.6.2 Exothera Major Business
2.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
2.6.4 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Exothera Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Viral Vector-Based Cell & Gene Therapy CDMO by Company Revenue
3.2.2 Top 3 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share in 2024
3.2.3 Top 6 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share in 2024
3.3 Viral Vector-Based Cell & Gene Therapy CDMO Market: Overall Company Footprint Analysis
3.3.1 Viral Vector-Based Cell & Gene Therapy CDMO Market: Region Footprint
3.3.2 Viral Vector-Based Cell & Gene Therapy CDMO Market: Company Product Type Footprint
3.3.3 Viral Vector-Based Cell & Gene Therapy CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value and Market Share by Type (2020-2025)
4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2025)
5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
6.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2020-2031)
6.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
6.3.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2031)
6.3.2 United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
6.3.3 Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
6.3.4 Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
7.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2031)
7.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
7.3.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2031)
7.3.2 Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7.3.3 France Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7.3.5 Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
7.3.6 Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region
8.3.1 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2020-2031)
8.3.2 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.3 Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.4 South Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.5 India Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
8.3.7 Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
9.2 South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2031)
9.3 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
9.3.1 South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2031)
9.3.2 Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
9.3.3 Argentina Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
10.3.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2031)
10.3.2 Turkey Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
10.3.4 UAE Viral Vector-Based Cell & Gene Therapy CDMO Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Viral Vector-Based Cell & Gene Therapy CDMO Market Drivers
11.2 Viral Vector-Based Cell & Gene Therapy CDMO Market Restraints
11.3 Viral Vector-Based Cell & Gene Therapy CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Viral Vector-Based Cell & Gene Therapy CDMO Industry Chain
12.2 Viral Vector-Based Cell & Gene Therapy CDMO Upstream Analysis
12.3 Viral Vector-Based Cell & Gene Therapy CDMO Midstream Analysis
12.4 Viral Vector-Based Cell & Gene Therapy CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2026-2031) & (USD Million)
Table 5. AGC Biologics Company Information, Head Office, and Major Competitors
Table 6. AGC Biologics Major Business
Table 7. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 8. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. AGC Biologics Recent Developments and Future Plans
Table 10. Lonza Company Information, Head Office, and Major Competitors
Table 11. Lonza Major Business
Table 12. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 13. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Lonza Recent Developments and Future Plans
Table 15. Charles River Laboratories Company Information, Head Office, and Major Competitors
Table 16. Charles River Laboratories Major Business
Table 17. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 18. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 20. Thermo Fisher Scientific Major Business
Table 21. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 22. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Thermo Fisher Scientific Recent Developments and Future Plans
Table 24. SK pharmteco Company Information, Head Office, and Major Competitors
Table 25. SK pharmteco Major Business
Table 26. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 27. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. SK pharmteco Recent Developments and Future Plans
Table 29. Exothera Company Information, Head Office, and Major Competitors
Table 30. Exothera Major Business
Table 31. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 32. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Exothera Recent Developments and Future Plans
Table 34. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million) by Players (2020-2025)
Table 35. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Players (2020-2025)
Table 36. Breakdown of Viral Vector-Based Cell & Gene Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 37. Market Position of Players in Viral Vector-Based Cell & Gene Therapy CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 38. Head Office of Key Viral Vector-Based Cell & Gene Therapy CDMO Players
Table 39. Viral Vector-Based Cell & Gene Therapy CDMO Market: Company Product Type Footprint
Table 40. Viral Vector-Based Cell & Gene Therapy CDMO Market: Company Product Application Footprint
Table 41. Viral Vector-Based Cell & Gene Therapy CDMO New Market Entrants and Barriers to Market Entry
Table 42. Viral Vector-Based Cell & Gene Therapy CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 43. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (USD Million) by Type (2020-2025)
Table 44. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Share by Type (2020-2025)
Table 45. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Forecast by Type (2026-2031)
Table 46. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025)
Table 47. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Forecast by Application (2026-2031)
Table 48. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 49. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 50. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 51. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 52. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2025) & (USD Million)
Table 53. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2026-2031) & (USD Million)
Table 54. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 55. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 56. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 57. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 58. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2025) & (USD Million)
Table 59. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2026-2031) & (USD Million)
Table 60. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 61. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 62. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 63. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 64. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2020-2025) & (USD Million)
Table 65. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2026-2031) & (USD Million)
Table 66. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 67. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 68. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 69. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 70. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2025) & (USD Million)
Table 71. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2026-2031) & (USD Million)
Table 72. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 73. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 74. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 75. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 76. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2025) & (USD Million)
Table 77. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2026-2031) & (USD Million)
Table 78. Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO Upstream (Raw Materials)
Table 79. Global Viral Vector-Based Cell & Gene Therapy CDMO Typical Customers
Table 1. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2026-2031) & (USD Million)
Table 5. AGC Biologics Company Information, Head Office, and Major Competitors
Table 6. AGC Biologics Major Business
Table 7. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 8. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. AGC Biologics Recent Developments and Future Plans
Table 10. Lonza Company Information, Head Office, and Major Competitors
Table 11. Lonza Major Business
Table 12. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 13. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Lonza Recent Developments and Future Plans
Table 15. Charles River Laboratories Company Information, Head Office, and Major Competitors
Table 16. Charles River Laboratories Major Business
Table 17. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 18. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 20. Thermo Fisher Scientific Major Business
Table 21. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 22. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Thermo Fisher Scientific Recent Developments and Future Plans
Table 24. SK pharmteco Company Information, Head Office, and Major Competitors
Table 25. SK pharmteco Major Business
Table 26. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 27. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. SK pharmteco Recent Developments and Future Plans
Table 29. Exothera Company Information, Head Office, and Major Competitors
Table 30. Exothera Major Business
Table 31. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product and Solutions
Table 32. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Exothera Recent Developments and Future Plans
Table 34. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue (USD Million) by Players (2020-2025)
Table 35. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Players (2020-2025)
Table 36. Breakdown of Viral Vector-Based Cell & Gene Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 37. Market Position of Players in Viral Vector-Based Cell & Gene Therapy CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 38. Head Office of Key Viral Vector-Based Cell & Gene Therapy CDMO Players
Table 39. Viral Vector-Based Cell & Gene Therapy CDMO Market: Company Product Type Footprint
Table 40. Viral Vector-Based Cell & Gene Therapy CDMO Market: Company Product Application Footprint
Table 41. Viral Vector-Based Cell & Gene Therapy CDMO New Market Entrants and Barriers to Market Entry
Table 42. Viral Vector-Based Cell & Gene Therapy CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 43. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (USD Million) by Type (2020-2025)
Table 44. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Share by Type (2020-2025)
Table 45. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Forecast by Type (2026-2031)
Table 46. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025)
Table 47. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Forecast by Application (2026-2031)
Table 48. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 49. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 50. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 51. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 52. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2025) & (USD Million)
Table 53. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2026-2031) & (USD Million)
Table 54. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 55. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 56. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 57. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 58. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2025) & (USD Million)
Table 59. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2026-2031) & (USD Million)
Table 60. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 61. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 62. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 63. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 64. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2020-2025) & (USD Million)
Table 65. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Region (2026-2031) & (USD Million)
Table 66. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 67. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 68. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 69. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 70. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2025) & (USD Million)
Table 71. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2026-2031) & (USD Million)
Table 72. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2020-2025) & (USD Million)
Table 73. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type (2026-2031) & (USD Million)
Table 74. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2020-2025) & (USD Million)
Table 75. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application (2026-2031) & (USD Million)
Table 76. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2020-2025) & (USD Million)
Table 77. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Country (2026-2031) & (USD Million)
Table 78. Global Key Players of Viral Vector-Based Cell & Gene Therapy CDMO Upstream (Raw Materials)
Table 79. Global Viral Vector-Based Cell & Gene Therapy CDMO Typical Customers
LIST OF FIGURES
Figure 1. Viral Vector-Based Cell & Gene Therapy CDMO Picture
Figure 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type in 2024
Figure 4. Adeno-associated Viral
Figure 5. Adenoviral
Figure 6. Lentiviral
Figure 7. Retroviral
Figure 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 9. Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application in 2024
Figure 10. Gene Therapy Picture
Figure 11. Cell Therapy Picture
Figure 12. Vaccine Development Picture
Figure 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Market Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 16. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Region (2020-2031)
Figure 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Region in 2024
Figure 18. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 19. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 20. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 21. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 22. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Players in 2024
Figure 25. Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 26. Market Share of Viral Vector-Based Cell & Gene Therapy CDMO by Player Revenue in 2024
Figure 27. Top 3 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share in 2024
Figure 28. Top 6 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share in 2024
Figure 29. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Share by Type (2020-2025)
Figure 30. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Type (2026-2031)
Figure 31. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Share by Application (2020-2025)
Figure 32. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Application (2026-2031)
Figure 33. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 34. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 35. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Country (2020-2031)
Figure 36. United States Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 37. Canada Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 38. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 39. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 40. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 41. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Country (2020-2031)
Figure 42. Germany Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 43. France Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 44. United Kingdom Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 45. Russia Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 46. Italy Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 47. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 48. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 49. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Region (2020-2031)
Figure 50. China Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 51. Japan Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 52. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 53. India Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 54. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 55. Australia Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 56. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 57. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 58. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Country (2020-2031)
Figure 59. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 60. Argentina Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 61. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 62. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 63. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Country (2020-2031)
Figure 64. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 65. Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 66. UAE Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 67. Viral Vector-Based Cell & Gene Therapy CDMO Market Drivers
Figure 68. Viral Vector-Based Cell & Gene Therapy CDMO Market Restraints
Figure 69. Viral Vector-Based Cell & Gene Therapy CDMO Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Viral Vector-Based Cell & Gene Therapy CDMO Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Viral Vector-Based Cell & Gene Therapy CDMO Picture
Figure 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type in 2024
Figure 4. Adeno-associated Viral
Figure 5. Adenoviral
Figure 6. Lentiviral
Figure 7. Retroviral
Figure 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 9. Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application in 2024
Figure 10. Gene Therapy Picture
Figure 11. Cell Therapy Picture
Figure 12. Vaccine Development Picture
Figure 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 14. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 15. Global Market Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 16. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Region (2020-2031)
Figure 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Region in 2024
Figure 18. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 19. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 20. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 21. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 22. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Players in 2024
Figure 25. Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 26. Market Share of Viral Vector-Based Cell & Gene Therapy CDMO by Player Revenue in 2024
Figure 27. Top 3 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share in 2024
Figure 28. Top 6 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share in 2024
Figure 29. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Share by Type (2020-2025)
Figure 30. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Type (2026-2031)
Figure 31. Global Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Share by Application (2020-2025)
Figure 32. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Application (2026-2031)
Figure 33. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 34. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 35. North America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Country (2020-2031)
Figure 36. United States Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 37. Canada Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 38. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 39. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 40. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 41. Europe Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Country (2020-2031)
Figure 42. Germany Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 43. France Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 44. United Kingdom Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 45. Russia Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 46. Italy Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 47. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 48. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 49. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Region (2020-2031)
Figure 50. China Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 51. Japan Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 52. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 53. India Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 54. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 55. Australia Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 56. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 57. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 58. South America Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Country (2020-2031)
Figure 59. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 60. Argentina Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 61. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Type (2020-2031)
Figure 62. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Application (2020-2031)
Figure 63. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value Market Share by Country (2020-2031)
Figure 64. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 65. Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 66. UAE Viral Vector-Based Cell & Gene Therapy CDMO Consumption Value (2020-2031) & (USD Million)
Figure 67. Viral Vector-Based Cell & Gene Therapy CDMO Market Drivers
Figure 68. Viral Vector-Based Cell & Gene Therapy CDMO Market Restraints
Figure 69. Viral Vector-Based Cell & Gene Therapy CDMO Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Viral Vector-Based Cell & Gene Therapy CDMO Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
